A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
721actual
Sites
43
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-24 | actual | When the study began enrolling |
| Primary completion | 2026-07-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-24 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Peripheral Neuropathic Pain
Intervention
- Other: No Drug
Primary outcome
what the primary-completion date above is the date OFProportion of participants with any treatment related adverse events (TRAEs)
measured Baseline to Week 14
Publications
- PMID 41849003 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed